R&D Strength

We have established an efficient R&D system that enables us to continuously develop drugs in high-potential therapeutic areas such as metabolic diseases, orthopedics, tumors and blood. Through more than 30 years of accumulation, our R&D team has accumulated extensive expertise in new drug discovery, efficacy evaluation, process and quality research, preclinical research, clinical research and regulatory filing.

Our R&D team has about 120 people, of which more than 60% have master's and doctoral degrees, covering multidisciplinary backgrounds. The main members of the R&D team have an average of more than 20 years of experience in the pharmaceutical industry. Due to our strong R&D capabilities, we participate in multiple national or provincial research projects. We have undertaken three major national science and technology projects, and our marketed products have won a total of 11 national honors. After more than 30 years of R&D efforts, we have established six product development platforms: recombinant protein drug technology platform, peptide drug technology platform, innovative drug-device combination technology platform, antibody drug technology platform, long-acting technology platform, and subcutaneous drug delivery technology platform, enabling us to continuously develop and advance pipeline products.